Alberto Esquenazi, MD
Physical Medicine & Rehabilitation · Philadelphia, PANPI 1801843859
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $207,205 of the $305,045 with a category attached, or 67.9%. 15 manufacturers reported payments, led by Ipsen Innovation at 46.4% of the total. Reporting peaked in 2019 at $103,433 and has fallen 75.3% since, to $25,521 in 2025. Among physical medicine & rehabilitation clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $1882.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$141K
- AbbVie$83K
- Ipsen Biopharm Limited$23K
- Ipsen Pharma SAS$22K
- Ipsen Biopharmaceuticals, Inc$13K
- Shionogi Inc$10K
- plus $13K from 9 others
Across 96 payments — averaging $1832.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$101K
- Ipsen Biopharmaceuticals, Inc$33K
- Pacira Pharmaceuticals Incorporated$17K
- Ossur Americas, Inc.$16K
- Merz Pharmaceuticals, LLC$5K
- Merz North America, Inc.$4K
What the payments were for
- Consulting fees$207,20568%
- Speaking & faculty fees$33,11911%
- Travel & lodging$63,03221%
- Food & beverage$1,6891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 47 | $141,466 |
| AbbVie(2 entities) | 65 | $82,517 |
| Ipsen Biopharm Limited | 9 | $23,217 |
| Ipsen Pharma SAS | 7 | $22,118 |
| Ipsen Biopharmaceuticals, Inc | 7 | $12,545 |
| Shionogi Inc | 10 | $9,950 |
| Ipsen Bioscience Inc. | 1 | $6,665 |
| Amneal Pharmaceuticals LLC | 2 | $5,400 |
| Pacira Pharmaceuticals Incorporated | 5 | $725 |
| Microtransponder, Inc. | 2 | $271 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Bayer | 2 | $50 |
| Boehringer Ingelheim | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$305,045 in reported general payments places this provider in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other physical medicine & rehabilitation in Philadelphia
- Kimberly HeckertPhiladelphia$119K
- Elaine HatchPhiladelphia$25K
- Benjamin AbramoffPhiladelphia$15K
- Ramesh GuptaPhiladelphia$14K
- Marisa MoretaPhiladelphia$13K
- M Quinn TatePhiladelphia$6K
- Benjamin KaplanPhiladelphia$5K
- Cameron OlezenePhiladelphia$4K
- Jeffery RoweKing Of Prussia$1.9M
- Michael SaulinoElkins Park$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.